{"id":"gc3110a-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine works by activating dendritic cells and T-cell responses against tumor antigens, enabling the patient's immune system to target and eliminate cancer cells. This approach aims to provide durable anti-tumor immunity by training the adaptive immune system to recognize cancer-specific epitopes.","oneSentence":"GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:43.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic cancer (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT03285997","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age","status":"UNKNOWN","sponsor":"Green Cross Corporation","startDate":"2017-09-30","conditions":"Influenza Vaccine","enrollment":260},{"nctId":"NCT02917304","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2016-10-10","conditions":"Influenza, Human","enrollment":274},{"nctId":"NCT02352584","phase":"PHASE3","title":"A Multicenter, Double-blind, Parallel Phase III Study","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1299},{"nctId":"NCT02121782","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-05","conditions":"Influenza","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GC3110A"],"phase":"phase_3","status":"active","brandName":"GC3110A vaccine","genericName":"GC3110A vaccine","companyName":"Green Cross Corporation","companyId":"green-cross-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Advanced or metastatic cancer (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}